Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study

Movement Disorders

Volumn 22, Issue 9, 2007, Pages 1258-1264

  Trosch, Richard M ^a   Adler, Charles H ^b   Pappert, Eric J ^c,d  

^a Parkinson's Disease and Movement Disorders Center   (United States)

^b MAYO CLINIC   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

BoNT B; Botulinum toxin type B; Hemifacial spasm; Myobloc

Indexed keywords

BOTULINUM TOXIN B;

ABNORMAL VISION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; EYE PAIN; FEMALE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEMIFACIAL SPASM; HUMAN; INJECTION SITE PAIN; LACRIMATION DISORDER; MALE; NAUSEA; PRIORITY JOURNAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VITAL SIGN; WEAKNESS; XEROSTOMIA;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HEMIFACIAL SPASM; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548232722     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21435     Document Type: Article

References (17)

1. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998;21:1740-1747.
2. Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmstead County, Minnesota, 1960 to 1984. Arch Neurol 1990;47:1233-1234.
3. Colosimo C, Bologna M, Lamberti S, et al. A comparative study of primary and secondary hemifacial spasm. Arch Neurol 2006;63:441-414.
4. Kemp LW, Reich SG. Hemifacial spasm. Curr Treat Options Neurol 2004;6:175-179.
5. Jannetta PJ. The cause of hemifacial spasm: definitive microsurgical treatment at the brainstem in 31 patients. Trans Am Acad Ophthalmol Otolaryngol 1975;80(3 Part 1):319-322.
6. Barker FJI, Jannetta PJ, Bissonette DJ, Shields PT, Larkins MV, Jho HD. Microvascular decompression for hemifacial spasm. J Neurosurg 1995;82:201-210.
7. National Institutes of Health: Consensus statement on the use of botulinum toxin. NIH 1990;8:20.
8. Tan N-C, Chan L-L, Tan E-K. Hemifacial spasm and involuntary facial movements. QJM 2002;95:493-500.
9. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2005;1:CD004899.
10. Colosimo C, Chianese M, Giovannelli M, Contarino MF, Bentivoglio AR. Botulinum toxin type B in blepharospasm and hemifacial spasm [letter]. J Neurol Neurosurg Psychiatry 2003;74:687.
11. Samanta JE, Stacy MA. Efficacy of botulinum toxin type B (Myobloc™) for treatment of blepharospasm: Report of 2 cases. Mov Disord 2002;17(Suppl 5):S286 (abstract).
12. Struck LK. Botulinum toxin type B (Myobloc™) for the treatment of hemifacial spasm and blepharospasm. Mov Disord 2002;17(Suppl 5):S278 (abstract).
13. Struck LK. Botulinum toxin type B (Myobloc™) for hemifacial spasm: report of three cases. Naunyn Schmiedeberg's Arch Pharmacol 2002;365(Suppl 2):R45 (abstract).
14. Tousi B, Jai S, Ahuja K, Ahmed A, Subramanian T. Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm [letter]. Parkinsonism Relat Disord 2004;10:455-456.
15. Molho ES, Factor SA. Clinical applications of botulinum toxin type B (BoB) in movement disorders. Mov Disord 2002;17(Suppl 5):S280 (abstract).
16. Chianese M, Giovannelli M, Contarino F, Bentivoglio A, Colosimo C. Botulinum neurotoxin B in blepharospasm and hemifacial spasm. Mov Disord 2002;17(Suppl 5):S277 (abstract).
17. Ahmed A, Kanwaljit A, Subramanian T, Perumal J. Treatment of hemifacial spasm with botulinum toxin-B (Myobloc). Mov Disord 2002;17(Suppl 5):S308-S309 (abstract).